| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |